United Therapeutics (UTHR) Stock
Lung disease drug maker funding organ transplant research. Here's the price, business snapshot, and what's worth knowing about United Therapeutics in August 2026.
United Therapeutics Corporation (UTHR) is a US-based biotechnology company focused on therapies for pulmonary arterial hypertension (PAH) and related rare diseases. It markets prostacyclin-class and inhaled therapies across intravenous, oral and inhalation routes, generating recurring revenues from long-term treatments. The company also invests heavily in organ manufacturing and regenerative medicine — including xenotransplantation and bioengineered-lung research — targeting chronic transplant shortages. Its financial profile blends cash-generating marketed drugs with high-risk, high-reward R&D programmes. Key considerations for investors include clinical trial outcomes, regulatory approvals, pricing and reimbursement dynamics, and patent lifecycles. Market capitalisation is around $19.11 billion, reflecting both existing product cash flows and longer-term innovation hopes. This summary aims to inform and educate; it is not personalised investment advice. Values can fall as well as rise, and prospective investors should consider their own risk tolerance and seek independent advice where appropriate.
Why It’s Moving
UTHR is moving on pipeline momentum as investors weigh strong earnings against softer revenue
- United Therapeutics said the FDA accepted its NDA for ralinepag, keeping a key pulmonary arterial hypertension pipeline asset moving toward a potential approval path.
- The company also said its TETON-PPF study of inhaled treprostinil reached full enrollment, which brings investors closer to a readout that could expand the franchise beyond current use.
- Second-quarter results showed earnings topping expectations even as revenue missed estimates, leaving the market focused on whether pipeline progress can offset near-term sales pressure.
UTHR is moving on pipeline momentum as investors weigh strong earnings against softer revenue
- United Therapeutics said the FDA accepted its NDA for ralinepag, keeping a key pulmonary arterial hypertension pipeline asset moving toward a potential approval path.
- The company also said its TETON-PPF study of inhaled treprostinil reached full enrollment, which brings investors closer to a readout that could expand the franchise beyond current use.
- Second-quarter results showed earnings topping expectations even as revenue missed estimates, leaving the market focused on whether pipeline progress can offset near-term sales pressure.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for UTHR is expected on November 4, 2026, and it will cover Q3 2026. This is based on the company’s usual reporting pattern and the currently estimated schedule. For investor planning, the report is typically released before market open.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying United Therapeutics' stock despite its current price being higher than the target.
Financial Health
United Therapeutics is performing well with strong profit margins and healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pulmonary therapies
Established PAH medicines provide recurring revenue and clinical data; watch trial readouts and competition, though outcomes can vary.
Organ manufacturing
Work on xenotransplantation and bioengineered lungs targets a major unmet need, but timelines and regulatory paths are long and uncertain.
Commercial footing
A largely US-driven revenue base with growing international reach; pricing, patents and reimbursement will shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
